Clinasia Labs Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 13-12-2024
- Paid Up Capital ₹ 1.91 M
as on 13-12-2024
- Company Age 19 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 127.49%
(FY 2022)
- Profit 49.79%
(FY 2022)
- Ebitda 52.68%
(FY 2022)
- Net Worth -38.34%
(FY 2022)
- Total Assets -41.83%
(FY 2022)
About Clinasia Labs
The Corporate was formerly known as Maxis Software Therapeutics Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 1.91 M, as per Ministry of Corporate Affairs (MCA) records.
Maulik Shah, Divya Eragam, and Eragamreddy Bharathi serve as directors at the Company.
- CIN/LLPIN
U72200TG2005PTC046712
- Company No.
046712
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jun 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Clinasia Labs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Maulik Shah  | Director | 29-Sep-2016 | Current |
| Divya Eragam | Director | 09-Jul-2011 | Current |
| Eragamreddy Bharathi | Director | 30-Jun-2005 | Current |
Financial Performance of Clinasia Labs.
Clinasia Labs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 127.49% increase. The company also saw a substantial improvement in profitability, with a 49.79% increase in profit. The company's net worth observed a substantial decline by a decrease of 38.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Clinasia Labs?
Unlock access to Clinasia Labs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Maxis Clinical Sciences LlpActive 2 years 11 monthsDivya Eragam and Eragamreddy Bharathi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Clinasia Labs?
Clinasia Labs has a workforce of 86 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Clinasia Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Clinasia Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
